En bloc resection for treatment of tumor-induced osteomalacia: a case presentation and a systematic review
- Tong Meng†1,
- Wang Zhou†1,
- Bo Li†1,
- Huabin Yin1,
- Zhenxi Li1,
- Lei Zhou1,
- Jinhai Kong1,
- Wangjun Yan1,
- Xinghai Yang1,
- Tielong Liu1,
- Dianwen Song1Email author and
- Jianru Xiao1Email author
© Meng et al.; licensee BioMed Central. 2015
Received: 28 November 2014
Accepted: 24 April 2015
Published: 8 May 2015
Tumor-induced osteomalacia (TIO) is a rare disorder, which is commonly found in craniofacial locations and in the extremities. To the best of our knowledge, only 16 cases have been described in the spine, and this is the first report to describe a case of patient with TIO in the thoracic spine combined with a mesenchymal hamartoma which had confused the therapeutic strategies to date.
We report the case of a 60-year-old patient with hypophosphatemia and presented with limb weakness. Treating with phosphate did not correct the hypophosphatemia and an 111In pentetreotide scintigraphy (octreotide scan) revealed an increased uptake at the right forearm. The tumor was resected totally, and the histopathology revealed a mesenchymal hamartoma, but we noticed that hypophosphatemia was not corrected after the tumor resection. Then a whole-body magnetic resonance imaging (WB-MRI) was performed and the results revealed tumorous tissues at the right T1 vertebral pedicle. The tumor was removed with an en bloc method, and the pathology showed phosphaturic mesenchymal tumor. Follow-up at 1 year after surgery revealed no recurrence, and the serum phosphorus level of the patient was normal.
Tumor-induced osteomalacia is exceedingly rare with only 16 cases in spine published in the literature. It is difficult to find and leads to years of suffering debilitating complications. In this regard, the WB-MRI is a better method to locate the real tumor. Treating with phosphate can only relieve symptoms, and a complete surgical removal remains the gold standard treatment.
KeywordsTumor-induced osteomalacia Phosphaturic mesenchymal tumor Hypophosphatemia Thoracic spine Tumor
Tumor-induced osteomalacia (TIO), also known as oncogenic osteomalacia, is a rare paraneoplastic syndrome, which is characterized by hyperphosphaturia, hypophosphatemia, and increased levels of alkaline phosphatase [1,2]. Clinical characteristics often include bone pain, pathologic fractures, and musculoskeletal weakness , which are related to renal phosphate wasting and resultant reduction in bone mineralization [2,4,5]. TIO was first described in 1947 by McCance and colleagues  who reported a 15-year-old girl exhibiting osteomalacia with vitamin D resistance. Unfortunately, he did not attribute her osteomalacia to femoral tumor.
In this report, we illustrate the clinical presentation and therapeutic strategy of a patient with a TIO in thoracic spine. He underwent an en bloc resection to attain oncological and metabolic control. To date, about 300 cases have been described in the world’s literature , and only 16 cases were located in the spine [5,8-19]. To our best knowledge, it is the first report to describe a mesenchymal hamartoma which confused the real location of TIO. In this report, we also comprehensively reviewed those cases of TIO in spine published in the English language literature, paying particular attention to the clinical presentation and therapeutic strategy of the reported tumors.
The patient, a 60-year-old man, first noticed pain in his right foot in 2007. In 2008, he came to the primary hospital presenting with low back pain, gait disturbance, and muscle weakness in the right lower limb. Radiological examination did not reveal any pathologic change in the lumbar vertebrae, whereas a bone scan revealed markedly increased bone uptake at the whole skeleton, and positron emission tomography/computed tomography (PET/CT) revealed mild increased uptake at multiple ribs and right femoral trochanter. No regular treatment was performed. Then the patient’s symptoms were progressively worsened and he became disabled. In 2010, blood examination revealed hypophosphatemia (0.5 mg/dl; normal range 0.98 to 1.62 mg/dl), hypocalcemia (2.17 mmol/L; normal range 2.25 to 2.75 mmol/L), reduced 1,25-dihydroxy vitamin D (10.5 pg/ml; normal range 11.1 to 42.9 pg/ml), and elevated β-C-terminal telopeptide of type I collagen (CTX) (1426 pg/L; normal range 100 to 650 pg/L). Osteomalacia was initially diagnosed and treated with phosphate, calcium, vitamin D, and calcitriol. Although blood examination still revealed hypophosphatemia (0.55 mg/dl), symptoms got better progressively. In 2012, an 111In pentetreotide scintigraphy (octreotide scan) was performed, and the result revealed a markedly increased uptake at the right forearm. The tumor was resected totally, and the histopathology revealed a mesenchymal hamartoma, but we noticed that hypophosphatemia wasn’t corrected after the tumor resection. In 2013, the patient suffered paraplegia and then a PET/CT scan was performed. Unfortunately, PET/CT scan did not locate the tumor, and thus, he underwent to a whole-body magnetic resonance imaging (WB-MRI), which revealed tumorous tissues at the right T1 vertebral pedicle.
The 60-year-old man was presented to our spine tumor center for consultation regarding resection of the tumor in the right T1 vertebral pedicle. On presentation to our center, the patient had signs of severe osteomalacia, and the patient’s most outstanding complaints were diffuse bone pain throughout the whole skeleton, limb weakness, hypaesthesia, and disabled walking. Physical examination revealed that motor strength was graded as 3/5 in the upper limbs and 1/5 in the lower limbs. Sensation decreased slightly throughout, with hyporeflexia. The Hoffmann sign and the Babinski sign were negative.
Blood tests revealed hypophosphatemia (0.51 mg/dl), hypocalcemia (2.15 mmol/L), elevated levels of parathyroid hormone (PTH) (72.3 pg/mL; normal range 12 to 65 pg/mL), normal serum alkaline phosphatase (ALP) levels (313 U/L; normal range 115 to 359 U/L), and normal levels of 1,25-dihydroxy vitamin D (21.01 pg/ml).
Characteristics of spinal cases of TIO
Boriani et al, 1978 
Bone pain, weakness
Hypophosphatemia, elevated ALP
Complete resection, radiotherapy
Stone et al, 1992 
Bone pain, weakness, fractures
Complete resection, supplementation of vitamin D, phosphate, and calcium
Yu et al, 1995 
Musculoskeletal pain, weakness
Hypophosphatemia, elevated ALP and PTH
Partial resection, supplementation of vitamin D and phosphate
Terek et al, 2001 
Bone pain, skeletal abnormalities
Hypophosphatemia, hypocalcemia, low level of vitamin D3, elevated ALP
Partial resection, chemotherapy (doxorubicin)
Dissanayake et al, 2003 
Musculoskeletal pains, fractures
Hypophosphatemia, low level of vit D3, elevated ALP
Folpe et al, 2004 
Partial resection, radiotherapy
Chua et al, 2008 
Musculoskeletal pain, fatigue
Hypophosphatemia, hypocalcemia, elevated ALP and PTH
Partial resection, supplementation of phosphate and calcitriol
Sciubba et al, 2009 
Bone pain, weakness, fractures
Hypophosphatemia, low level of vitamin D3, elevated ALP and PTH
Pirola et al, 2009 
Hypophosphatemia, low level of vitamin D3, elevated ALP and PTH
Complete resection, supplementation of vitamin D and phosphate
Mavrogenis et al, 2010 
Bone pain, paresthesias
Marshall et al, 2010 
Bone pain; fractures
Akhter et al, 2011 
Complete resection, supplementation of vitamin D, and phosphate
Gandhi et al, 2012 
Bone pain, weakness
Hypophosphatemia, hypocalcemia, low level of vit D3, elevated ALP and PTH
Nakamura et al, 2014 
Hypophosphatemia, elevated ALP and PTH
Complete resection, supplementation of phosphate and calcitriol.
Puthenveetil et al 
Musculoskeletal pain, weakness, fractures
Hypophosphatemia, increased ALP
Complete resection, supplementation of calcium and phosphate
Bone pain, weakness, paresthesia
Hypophosphatemia, hypocalcemia, elevated PTH
Complete resection, supplementation of calcitriol
TIO can lead to debilitating complications and years of suffering. The average age of 16 cases is 48.0 (range 14 to 72) years. It occurs in any age, with preponderance around the fifth decades. Characteristically, TIO affects adults without a predilection for gender, with nine female and seven male in all the spinal TIOs. Diffuse bone pain, caused by poor bone mineralization, is the most frequent symptom in these patients . If treated inadequately, severe osteomalacia may lead to progressive myalgias in adults and gait disturbances, growth stunting, and skeletal deformities in children .
Notably, one of the most challenging aspects of TIO is to find the tumor. The occult nature of TIO delays its recognition, and in our case, we employed 6 years to identify the real tumor which may attribute to the mesenchymal hamartoma in the same patient complicating the final diagnosis. In a literature review of all the TIOs , the average time from onset of symptoms to a confirmed diagnosis often exceeds 2.5 years. Definitive treatment is further delayed by an average of 5 years due to inability to find the underlying tumor due to the characteristics of being small and slow growing and being located in peculiar or atypical sites.
Typical laboratory findings include hyperphosphaturia, elevated ALP, and low serum levels of vitamin D3, which account for 14/15, 10/15, and 5/15 in the literature, respectively [1,22]. Hypophosphatemia is secondary to inhibition of renal phosphorus reabsorption, and the vitamin D synthetic defect blocks the compensatory rise of calcitriol stimulated by the hypophosphatemia . Moreover, fibroblast growth factor-23 (FGF-23), associated with iron in a pathophysiological mechanism of TIO [23,24], is highly expressed in TIO tumors compared with normal tissues [1,20,21].
Radiographically, it presents with bone cortical thickness, osteoporosis, and fracture . Unfortunately, TIO tumors could not be detected by conventional imaging techniques in all 16 cases. The classic detecting method of TIO is 111In pentetreotide scintigraphy (octreotide scan), a scanning technique that detects the expression of somatostatin receptors (SSTRs) [26,27]. However, a nonspecific uptake may cause a false-positive scan due to inflammatory tissues, fractures, or other tumor, as lymphocytes can express octreotide receptors, and moreover, a negative octreotide scan cannot exclude a diagnosis of TIO. False-positive scan emphasizes the need to further identify the tumor by PET/CT or WB-MRI exams. Successful tumor localization has also been reported in some patients with PET/CT [28,29]. However, considering the small and occult nature of TIO, it might not be seen as increased uptake of PET/CT utilization . WB-MRI has been well established to have no radiological exposure and offers excellent contrast resolution of bone, soft tissue, and subcutaneous regions. Moreover, majority of TIOs which had been reported to be located in the bone, soft tissue, and subcutaneous region have a small size. Accordingly, WB-MRI is advantageous for detecting such kinds of tumor [31,32].
The ideal treatment for TIO is complete tumor resection, and this corrects the biochemical abnormalities and remineralizes the bone substance in most cases (12/16) . The partial resection (4/16) might also lead to persistent serum abnormalities remained or even tumor recurrence (#6). It is worth noting that osteomalacia may reduce bone resistance and increase the risk of nonunion or lead to delayed union . Therefore, rigid internal fixation and effective brace should be insured [35,36]. With regard to TIO without accurate location, the combination of vitamin D, phosphorus supplementation, and calcitriol can be used to replace progressive renal phosphorus loss, promote renal production of 1,25-dihydroxy vitamin D, and enhance renal phosphorus reabsorption. However, medical therapy cannot maintain long-term efficacy and potential complications should also be watched out, such as hyperparathyroidism, hypercalcemia, and kidney stone formation .
Tumor-induced osteomalacia is exceedingly rare with only 16 cases in spine published in the literature. It is difficult to find and leads to years of suffering debilitating complications. In this regard, WB-MRI is one of the important options to detect the real tumor. Treating with phosphate can only relieve symptoms, and completing surgical removal remains the modality of choice.
Written informed consent was obtained from each patient for publication of this study and the accompanying images.
We thank Dr. Chunyan Xia who prepared pathological images. We thank all patients and their families who agreed to publish the clinical data.
- de Beur SM J. Tumor-induced osteomalacia. JAMA. 2005;294:1260–7.View ArticleGoogle Scholar
- Econs MJ, Drezner MK. Tumor-induced osteomalacia - unveiling a new hormone. N Engl J Med. 1994;330:1679–81.View ArticlePubMedGoogle Scholar
- Carpenter TO. Oncogenic osteomalacia - a complex dance of factors. N Engl J Med. 2003;348:1705–8.View ArticlePubMedGoogle Scholar
- Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer. 1987;59:1442–54.View ArticlePubMedGoogle Scholar
- Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28:1–30.View ArticlePubMedGoogle Scholar
- Mc CR. Osteomalacia with Looser’s nodes (Milkman’s syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 1947;16:33–46.Google Scholar
- Jiang Y, Xia WB, Xing XP, Silva BC, Li M, Wang O, et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res. 2012;27:1967–75.View ArticlePubMedGoogle Scholar
- Boriani S, Campanacci M. Osteoblastoma associated with osteomalacia (presentation of a case and review of the literature). Ital J Orthop Traumatol. 1978;4:379–82.PubMedGoogle Scholar
- Stone MD, Quincey C, Hosking DJ. A neuroendocrine cause of oncogenic osteomalacia. J Pathol. 1992;167:181–5.View ArticlePubMedGoogle Scholar
- Yu GH, Katz RL, Raymond AK, Gagel RF, Allison A, McCutcheon I. Oncogenous osteomalacia: fine needle aspiration of a neoplasm with a unique endocrinologic presentation. Acta Cytol. 1995;39:831–2.PubMedGoogle Scholar
- Terek RM. Nielsen GP:Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 29-2001. A 14-year-old with abnormal bones and a sacral mass. N Engl J Med. 2001;345:903–8.View ArticleGoogle Scholar
- Chua SC, O’Connor SR, Wong WL, Ganatra RH. Case report: solitary plasmacytoma of bone with oncogenic osteomalacia: recurrence of tumour confirmed by PET/CT. A case report with a review of the radiological literature. Br J Radiol. 2008;81:e110–114.View ArticlePubMedGoogle Scholar
- Sciubba DM, Petteys RJ, Shakur SF, Gokaslan ZL, McCarthy EF, Collins MT, et al. En bloc spondylectomy for treatment of tumor-induced osteomalacia. J Neurosurg Spine. 2009;11:600–4.View ArticlePubMedGoogle Scholar
- Pirola E, Vergani F, Casiraghi P, Leone EB, Guerra P, Sganzerla EP. Oncogenic osteomalacia caused by a phosphaturic mesenchymal tumor of the thoracic spine. J Neurosurg Spine. 2009;10:329–33.View ArticlePubMedGoogle Scholar
- Mavrogenis AF, Sakellariou VI, Soultanis K, Mahera H, Korres DS, Papagelopoulos PJ. A nonphosphaturic mesenchymal tumor mixed connective tissue variant of the sacrum. Orthopedics. 2010;33:851.PubMedGoogle Scholar
- Marshall AE, Martin SE, Agaram NP, Chen JH, Horn EM, Douglas-Akinwande AC, et al. A 61-year-old woman with osteomalacia and a thoracic spine lesion. Brain Pathol. 2010;20:499–502.View ArticlePubMedGoogle Scholar
- Akhter M, Sugrue PA, Bains R, Khavkin YA. Oncogenic osteomalacia of the cervical spine: a rare case of curative resection and reconstruction. J Neurosurg Spine. 2011;14:453–6.View ArticlePubMedGoogle Scholar
- Gandhi GY, Shah AA, Wu KJ, Gupta V, Shoraka AR. Tumor-induced osteomalacia caused by primary fibroblast growth factor 23 secreting neoplasm in axial skeleton: a case report. Case Rep Endocrinol. 2012;2012:185454.PubMed CentralPubMedGoogle Scholar
- Nakamura T, Aizawa T, Hoshikawa T, Ozawa H, Ito N, Fukumoto S, et al: Tumor-induced osteomalacia caused by phosphaturic mesenchymal tumor of the cervical spine. J Orthop Sci 2014 DOI: 10.1007/s00776-014-0540-4Google Scholar
- Rodgers SE, Perrier ND. Parathyroid carcinoma. Curr Opin Oncol. 2006;18:16–22.View ArticlePubMedGoogle Scholar
- Vollbrecht JE, Rao DS. Images in clinical medicine. Tumor-induced osteomalacia N Engl J Med. 2008;358:1282.View ArticleGoogle Scholar
- Khosravi A, Cutler CM, Kelly MH, Chang R, Royal RE, Sherry RM, et al. Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab. 2007;92:2374–7.View ArticlePubMedGoogle Scholar
- Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009;45:814–6.View ArticlePubMedGoogle Scholar
- Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009;94:2332–7.View ArticlePubMedGoogle Scholar
- Cukierman T, Gatt ME, Hiller N, Chajek-Shaul T. Clinical problem-solving. A fractured diagnosis. N Engl J Med. 2005;353:509–14.View ArticlePubMedGoogle Scholar
- Palot Manzil FF, Bhambhvani PG, O’Malley JP. Evaluation of tumor-induced osteomalacia with 111In-pentetreotide scintigraphy. J Nucl Med Technol. 2013;41:299–301.View ArticlePubMedGoogle Scholar
- Nguyen BD, Wang EA. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin Nucl Med. 1999;24:130–1.View ArticlePubMedGoogle Scholar
- Hesse E, Moessinger E, Rosenthal H, Laenger F, Brabant G, Petrich T, et al. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res. 2007;22:158–62.View ArticlePubMedGoogle Scholar
- Roarke MC, Nguyen BD. PET/CT localization of phosphaturic mesenchymal neoplasm causing tumor-induced osteomalacia. Clin Nucl Med. 2007;32:300–1.View ArticlePubMedGoogle Scholar
- Nakanishi K, Sakai M, Tanaka H, Tsuboi H, Hashimoto J, Hashimoto N, et al. Whole-body MR imaging in detecting phosphaturic mesenchymal tumor (PMT) in tumor-induced hypophosphatemic osteomalacia. Magn Reson Med Sci. 2013;12:47–52.View ArticlePubMedGoogle Scholar
- Fukumoto S, Takeuchi Y, Nagano A, Fujita T. Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone. 1999;25:375–7.View ArticlePubMedGoogle Scholar
- Nelson AE, Mason RS, Robinson BG, Hogan JJ, Martin EA, Ahlstrom H, et al. Diagnosis of a patient with oncogenic osteomalacia using a phosphate uptake bioassay of serum and magnetic resonance imaging. Eur J Endocrinol. 2001;145:469–76.View ArticlePubMedGoogle Scholar
- Shane E, Parisien M, Henderson JE, Dempster DW, Feldman F, Hardy MA, et al. Tumor-induced osteomalacia: clinical and basic studies. J Bone Miner Res. 1997;12:1502–11.View ArticlePubMedGoogle Scholar
- Mankin HJ. Rickets, osteomalacia, and renal osteodystrophy. Part II J Bone Joint Surg Am. 1974;56:352–86.Google Scholar
- Meng T, Yin H, Li Z, Li B, Zhou W, Wang J, et al. Therapeutic strategy and outcome of spine tumors in pregnancy: a report of 21 cases and literature review. Spine (Phila Pa 1976). 2015;40:E146–153.View ArticleGoogle Scholar
- Meng T, Yin H, Li B, Li Z, Xu W, Zhou W, et al. Clinical features and prognostic factors of patients with chordoma in the spine: a retrospective analysis of 153 patients in a single center. Neuro Oncol. 2015;17:725–32.View ArticlePubMedGoogle Scholar
- Dissanayake AM, Wilson JL, Holdaway IM, Reid IR. Oncogenic osteomalacia: culprit tumour detection whole body magnetic resonance imaging. Intern Med J. 2003;33:615–6.View ArticlePubMedGoogle Scholar
- Puthenveetil PJ, Hattab EM, Peacock M, Horn EM. Thoracic phosphaturic mesenchymal tumors causing oncogenic osteomalacia. J Clin Neurosci. 2013;20:1057–61.View ArticlePubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.